Importantly, IBI3019 not only demonstrated superior in vitro and in vivo anti-tumor efficacy to Cetuximab and Amivantamab but was also highly tolerable in cynomolgus monkeys with HNSTD at 150 mg ...

Importantly, IBI3019 not only demonstrated superior in vitro and in vivo anti-tumor efficacy to Cetuximab and Amivantamab but was also highly tolerable in cynomolgus monkeys with HNSTD at 150 mg/kg in ...

Importantly, IBI3019 not only demonstrated superior in vitro and in vivo anti-tumor efficacy to Cetuximab and Amivantamab but was also highly tolerable in cynomolgus monkeys with HNSTD at 150 mg/kg in ...

The application includes an every-three-week (Q3W) amivantamab regimen in combination with carboplatin and pemetrexed. This would be for adult patients with advanced non-small cell lung cancer (NSCLC) ...

Janssen-Cilag International NV, a Johnson & Johnson company, has submitted an application to the European Medicines Agency (EMA) to extend the marketing authorisation for RYBREVANT (amivantamab) with ...

Johnson & Johnson has filed its bispecific antibody amivantamab to the FDA, hoping to muscle into the big market for drugs that are used to treat EGFR-positive non-small cell lung cancer (NSCLC).

Another recent entrant is Johnson & Johnson's Rybrevant (amivantamab), a bispecific antibody targeting c-Met and EGFR, which is currently approved for EGFR-mutated NSCLC only. Analysts have ...

These include a threefold decrease in infusion-related reactions with Darzalex subcutaneous administration, a fivefold reduction with amivantamab subQ, and an exploratory analysis indicating that ...

Cetuximab therapy was started on the day radiation therapy began with a loading dose of 400 mg/m 2 in the first week, and then 250 mg/m 2 /week for the successive radiation weeks. One cycle of ...